Krishnan Singhan T M, Quattrini Cristian, Jeziorska Maria, Malik Rayaz A, Rayman Gerry
The Diabetes Centre, Ipswich Hospital, Ipswich, UK.
Diabetes Care. 2009 Mar;32(3):451-5. doi: 10.2337/dc08-1453. Epub 2008 Dec 15.
Abnormal small nerve fiber function may be an early feature of diabetic neuropathy and may also underlie painful symptoms. Methods for assessing small-fiber damage include quantitative sensory testing (QST) and determining intraepidermal nerve fiber density. We recently described a reproducible physiological technique, the LDIflare, which assesses small-fiber function and thus may reflect early dysfunction before structural damage. The value of this technique in painful neuropathy was assessed by comparing it with QST and dermal nerve fiber density (NFD).
Fifteen healthy control subjects, 10 subjects with type 2 diabetes and painful neuropathy (PFN), and 12 subjects with type 2 diabetes and painless neuropathy (PLN) were studied. LDIflare and QST were performed on the dorsum of the foot, and dermal NFD was determined.
Results of both large- and small-fiber quantitative sensory tests were abnormal in patients with PLN but not those with PFN compared with control subjects. Dermal NFD was also significantly reduced in the PLN group compared with control subjects (205.8 +/- 165.3 vs. 424.9 +/- 176.3 [mean +/- SD]; P = 0.003) but not in the PFN group (307.6 +/- 164.5). In contrast, the LDIflare (square centimeters) was reduced in both PFN (1.59 +/- 0.41) and PLN (1.51 +/- 0.56) groups compared with control subjects (4.38 +/- 1.4) (P < 0.001 for both). NFD correlated significantly with the LDIflare (r = 0.57, P < 0.0001).
The LDIflare demonstrated impaired small-fiber function in patients with PFN when other assessments revealed no abnormality. We believe that this method has potential diagnostic value, particularly because it is noninvasive, has excellent reproducibility, and correlates with NFD. Furthermore, it may have an important role in assessing preventative therapies in early neuropathy.
异常的小神经纤维功能可能是糖尿病神经病变的早期特征,也可能是疼痛症状的潜在原因。评估小纤维损伤的方法包括定量感觉测试(QST)和测定表皮内神经纤维密度。我们最近描述了一种可重复的生理技术,即激光散斑成像血流测定法(LDIflare),它可评估小纤维功能,因此可能反映出结构损伤之前的早期功能障碍。通过将该技术与QST和真皮神经纤维密度(NFD)进行比较,评估了其在疼痛性神经病变中的价值。
对15名健康对照者、10名2型糖尿病伴疼痛性神经病变(PFN)患者和12名2型糖尿病伴无痛性神经病变(PLN)患者进行了研究。在足背进行LDIflare和QST检查,并测定真皮NFD。
与对照者相比,PLN患者的大纤维和小纤维定量感觉测试结果均异常,但PFN患者无异常。与对照者相比,PLN组的真皮NFD也显著降低(205.8±165.3对424.9±176.3[平均值±标准差];P=0.003),而PFN组未降低(307.6±164.5)。相比之下,与对照者(4.38±1.4)相比,PFN组(1.59±0.41)和PLN组(1.51±0.56)的LDIflare(平方厘米)均降低(两组P均<0.001)。NFD与LDIflare显著相关(r=0.57,P<0.0001)。
当其他评估显示无异常时,LDIflare显示PFN患者存在小纤维功能受损。我们认为该方法具有潜在的诊断价值,特别是因为它是非侵入性的,具有出色的可重复性,并且与NFD相关。此外,它可能在评估早期神经病变的预防治疗中发挥重要作用。